Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Migra-Zen Relief Plus
- Development stage
- Unknown
- Lead developer
- RZN Nutraceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Migra-Zen Relief Plus is an all-natural herbal dietary supplement developed by ZenMed for the prophylactic treatment of chronic migraine headaches. The formulation is designed to reduce the frequency and severity of migraine attacks by utilizing a blend of botanical extracts and minerals. Common ingredients in the Migra-Zen line include feverfew (*Tanacetum parthenium*), butterbur (*Petasites hybridus*), riboflavin (Vitamin B2), and magnesium. These components are thought to work synergistically to inhibit neuroinflammation, modulate vascular tone, and reduce neuronal hyperexcitability. A randomized, double-blind, placebo-controlled clinical trial (NCT01135784) was initiated to evaluate the efficacy and safety of the product, including its impact on liver enzymes and urinalysis, though the study's current status is unknown.
- Brand names
- Migra-Zen Relief PlusMigra-Zen
- Other names
- ZenMed Migra-Zen
02
Targets
NF-κBNMDAR (Glutamate receptor ionotropic, NMDA)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on Migra-Zen Relief Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Migra-Zen Relief Plus.